Sana Biotechnology announced positive preliminary 12-week clinical results for its type 1 diabetes study, showing promising outcomes for hypoimmune-modified pancreatic islet cells. These cells, transplanted without immunosuppression, demonstrated the ability to overcome immune recognition and maintain stable C-peptide production.